Abstract
The diacylglycerol-responsive C1 domains of protein kinase C and of the related classes of signaling proteins represent highly attractive targets for drug development. The signaling functions that are regulated by C1 domains are central to cellular control, thereby impacting many pathological conditions. Our understanding of the diacylglycerol signaling pathways provides great confidence in the utility of intervention in these pathways for treatment of cancer and other conditions. Multiple compounds directed at these signaling proteins, including compounds directed at the C1 domains, are currently in clinical trials, providing strong validation for these targets. Extensive understanding of the structure and function of C1 domains, coupled with detailed insights into the molecular details of ligand – C1 domain interactions, provides a solid basis for rational and semi-rational drug design. Finally, the complexity of the factors contributing to ligand – C1 domain interactions affords abundant opportunities for manipulation of selectivity; indeed, substantially selective compounds have already been identified.
Keywords: Protein kinase C, phorbol ester, RasGRP, bryostatin, C1 domain
Current Drug Targets
Title: Wealth of Opportunity - The C1 Domain as a Target for Drug Development
Volume: 9 Issue: 8
Author(s): P. M. Blumberg, N. Kedei, N. E. Lewin, D. Yang, G. Czifra, Y. Pu, M. L. Peach and V .E. Marquez
Affiliation:
Keywords: Protein kinase C, phorbol ester, RasGRP, bryostatin, C1 domain
Abstract: The diacylglycerol-responsive C1 domains of protein kinase C and of the related classes of signaling proteins represent highly attractive targets for drug development. The signaling functions that are regulated by C1 domains are central to cellular control, thereby impacting many pathological conditions. Our understanding of the diacylglycerol signaling pathways provides great confidence in the utility of intervention in these pathways for treatment of cancer and other conditions. Multiple compounds directed at these signaling proteins, including compounds directed at the C1 domains, are currently in clinical trials, providing strong validation for these targets. Extensive understanding of the structure and function of C1 domains, coupled with detailed insights into the molecular details of ligand – C1 domain interactions, provides a solid basis for rational and semi-rational drug design. Finally, the complexity of the factors contributing to ligand – C1 domain interactions affords abundant opportunities for manipulation of selectivity; indeed, substantially selective compounds have already been identified.
Export Options
About this article
Cite this article as:
Blumberg M. P., Kedei N., Lewin E. N., Yang D., Czifra G., Pu Y., Peach L. M. and Marquez .E. V, Wealth of Opportunity - The C1 Domain as a Target for Drug Development, Current Drug Targets 2008; 9 (8) . https://dx.doi.org/10.2174/138945008785132376
DOI https://dx.doi.org/10.2174/138945008785132376 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Wheel of Fortune – Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics
Current Chemical Biology Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Interactome Analysis of the Differentially Expressed Proteins in Uterine Leiomyoma
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Cosmeceutical Aptitudes of Azelaic Acid
Current Drug Research Reviews Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design The Role of WNT in Rheumatoid Arthritis and its Therapeutic Implication
Mini-Reviews in Medicinal Chemistry The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Current Signal Transduction Therapy Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Current Pharmaceutical Design Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry